Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis

References

• Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703.
   PubMed Web of Science ®Google Scholar
• Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA. 2000;97:1230–5.
   PubMed Web of Science ®Google Scholar
• Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem. 1999;274:13733–6.
   PubMed Web of Science ®Google Scholar
• Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–92.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, et al. DcR3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 2007;57:1067–75.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498–502.
   PubMed Web of Science ®Google Scholar
• Steinbrocker 0, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659–62.
   Google Scholar
• van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the devel-opment of a disease activity score. Ann Rheum Dis. 1990; 49:916–20.
   Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
   Google Scholar
• Chou CT, Yang JS, Lee MR. Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bc1-2 in rheumatoid synovial tissues. J Pathol. 2001;193: 110–6.
   Google Scholar
• Tak PP, Zvaifler NJ, Green DR, Firestein GS. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today. 2000;21:78–82.
   PubMedGoogle Scholar
• Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304–9.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Liithy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207–29.
   PubMed Web of Science ®Google Scholar
• Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheu-matoid arthritis. Clin Immunol. 2008;129:249–55.
   PubMed Web of Science ®Google Scholar
• Lee CS, Hu CY, Tsai HF, Wu CS, Hsieh SL, Liu LC, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol. 2008; 151:383–90.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kollias G. Tumor necrosis factor biology in exper-imental and clinical arthritis. Curr Opin Rheumatol. 2003; 15:380–6.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Kalden JR. The balance of Thl/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15: 677–91.
   Google Scholar
• Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother. 2007;8:2089–107.
   PubMed Web of Science ®Google Scholar
• Tetta C, Camussi G, Modena V, Vittorio CD, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49:665–7.
   Google Scholar
• Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis. 2003;62:472�5.
   Web of Science ®Google Scholar
• Petrovic RL, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol. 2006;25:448–52.
   PubMedGoogle Scholar
• Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J. 2006;99:1078–83.
   PubMed Web of Science ®Google Scholar
• Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, et al. IGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum. 2006;54:1451–62.
   PubMedGoogle Scholar
• Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE. The TNF superfamily member LIGHT contributes to sur-vival and activation of synovial fibroblasts in rheumatoid arthri-tis. Rheumatology. 2007;46:1063–70.
   PubMed Web of Science ®Google Scholar